Clearside Biomedical Inc (FRA:CLM)
€ 0.885 0.065 (7.93%) Market Cap: 69.14 Mil Enterprise Value: 47.25 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Clearside Biomedical Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 19, 2023 / 05:30PM GMT
Release Date Price: €0.96 (-2.04%)
Serge Belanger
Needham & Company, LLC - Moderator

Good afternoon. I'm Serge Belanger, one of the senior healthcare analysts at Needham. I want to welcome you to our 22nd Annual Healthcare Conference.

For our next session, we're going to be talking with Clearside Biomedical. And we have the company's CEO, George Lasezkay, with us today, who's going to give us an overview and talk about the recently unveiled Phase 2b trial design called -- from the ODYSSEY trial. So I'll hand it over to George, and you can give us the overview.

George Lasezkay
Clearside Biomedical, Inc. - President & CEO

All right. Thanks, Serge. Appreciate being invited to be part of the Needham Conference, and it's our pleasure and privilege to be here.

And so let me just take you through just some very brief slides about the company and then we'll get into what we recently announced yesterday, which was our plans and our design for our Phase 2b trial with our tyrosine kinase inhibitor, axitinib, in Wet AMD patients.

During this presentation, I will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot